Immunotherapy before surgery for triple-negative breast cancer — why it starts before the operation

Most breast cancer patients are not candidates. Immunotherapy before surgery is considered in triple-negative disease only, and inside it only where the tumour is larger or the lymph nodes are involved — broadly stage II and stage III. Small node-negative tumours, hormone-receptor-positive cancers and HER2-positive cancers sit outside this group.

That arithmetic is worth stating before anything else, because “immunotherapy before surgery” is now a phrase families hear at diagnosis and start searching immediately. Triple-negative disease is roughly one in eight to one in six breast cancers. It is the smallest of the three main subtypes, and it is the one where NCCN, ASCO and ESMO describe a defined place for checkpoint inhibitor immunotherapy. Every other subtype is treated with other tools, and that is not lesser care.

Even within triple-negative disease, the pre-surgery route is not automatic. It is described for higher-risk early disease — a tumour above a certain size, or involved lymph nodes. A woman with a small, node-negative triple-negative tumour is usually offered surgery first, with chemotherapy and radiation therapy as indicated. Active autoimmune disease, a significant steroid dose being taken for another illness, an organ transplant or poor organ function can also make checkpoint immunotherapy unsuitable, whatever the stage says.

Neoadjuvant simply means before surgery. Adjuvant means after it. Nothing else about the words is technical. What changes is the order: the drug treatment is given first, over months, and the operation follows it. The surgery still happens. The chemotherapy still happens. Immunotherapy is added to the chemotherapy given first, never given instead of it.

Immunotherapy on this page means immune checkpoint inhibitors as a drug class. This page names no medicine and no brand, and it recommends no treatment. At CION, immunotherapy is given as day care at our centres when it is genuinely indicated, every plan is set by a tumour board rather than by one doctor, and any cost discussed with you is indicative, as of August 2026, and confirmed in writing before treatment starts.

Because the tumour is still there. Treatment given before surgery can shrink it, which sometimes allows a smaller operation. It also leaves a readable result: the pathologist can see how much cancer the treatment cleared. Guidelines describe this sequence for higher-risk triple-negative disease specifically, not for breast cancer in general.

If your report says triple-negative but you are not yet sure where immunotherapy fits at all, start with our wider guide to immunotherapy for triple-negative breast cancer, which sets out early and advanced disease side by side. This page assumes surgery is on the table and the question is what comes first.

It means the pathologist found no invasive cancer left in the breast tissue or in the lymph nodes that surgery removed. It is written on your surgical pathology report, usually one to two weeks after the operation. Doctors shorten it to pCR. It is a favourable early marker, not a promise about the years ahead.

This is the part of the plan patients hold on to, and it is worth understanding properly rather than half-understood. When treatment is given before surgery, the tissue that comes out is evidence. A pathologist cuts it, stains it and looks at it under a microscope, along with every lymph node removed at the same operation. What they write down is a direct record of what the months of treatment did to your cancer. No scan gives you that. Nothing available before surgery gives you that.

A complete response is reported when no invasive cancer is found in either place. Ductal carcinoma in situ — cancer cells still contained inside a duct — may still be described on the report, and by the usual definition its presence does not cancel a complete response. If you see it mentioned, ask your oncologist to point to the exact line, because it is one of the most commonly misread parts of the report.

A pathological complete response describes what was in the tissue that came out on the day of your operation. It is a marker used in guidelines and in research, and NCCN, ASCO and ESMO patient-education material treats it as favourable. It is not a prediction for you as an individual, no number on this page is attached to it, and follow-up appointments continue either way. Equally, residual disease is common and is not a failed treatment — it changes the conversation after surgery rather than ending it.

Usually for several more months. In the schedule guidelines describe, immunotherapy runs with chemotherapy for roughly six months before surgery, then continues on its own for roughly six months after it. End to end, the whole course sits close to a year from your first cycle to your last.

1. 1

   Diagnosis, staging and the tumour board

   Receptor testing confirms triple-negative disease. Scans and examination set the stage, the tumour size and the node status. The medical, surgical and radiation oncologists review the file together and decide whether the drug treatment goes first. This is also the point to raise fertility, because the discussion belongs before the first cycle, not after it.

2. 2

   The months before surgery

   Immunotherapy is given alongside chemotherapy, in cycles a few weeks apart, across roughly six months. Each infusion is day care at a CION centre — a few hours in the chair, then home the same day. The tumour is checked through this phase, and response-assessment imaging is coordinated at our partner imaging centres rather than done in-house.

3. 3

   Surgery, then the report

   The operation is planned once the pre-surgery phase is complete, with a short gap to let the last cycle settle. The removed tissue and lymph nodes go to pathology. The report comes back in one to two weeks and is the single most informative document you will receive in the whole plan.

4. 4

   The months after surgery

   Immunotherapy is usually continued on its own for roughly six months more. In the standard schedule this part is completed whether or not a complete response was found, which surprises many patients — ask your oncologist to explain the reasoning for your case. Radiation therapy is planned in parallel where it is indicated.

5. 5

   Finishing, and what follow-up looks like

   The course has a defined end. Immune-related side effects can still begin weeks or months after the last cycle, particularly in the thyroid, bowel, lungs, liver and skin, so tell any doctor you see afterwards that you have had immunotherapy. Follow-up appointments continue on a set schedule regardless of what the pathology report said.

Schedules differ between teams and can be shortened if side effects require it. Ask for the planned number of cycles, before and after surgery, to be written on your treatment summary, and ask what the full plan costs — indicative, as of August 2026 — including what Aarogyasri, CGHS, ECHS, ESI or your insurance is expected to cover.

Most of the confusion about treatment before surgery comes from two people answering different halves of the question. Ask these six in one appointment, with your surgeon and your medical oncologist in the room together where possible, and you will have a complete answer either way.

• Is my disease triple-negative, and what is the tumour size and node status that puts me in or out of this group?
• Are we treating before surgery or operating first, and what is the reason for that order in my case?
• How many cycles are planned before surgery, and how many after it?
• What will the pathology report after surgery tell us, and what would change depending on what it says?
• If I am not a candidate for immunotherapy, what is doing the work in my plan instead?
• What does the full plan cost, and what will insurance or a government scheme cover?

One question deserves to be asked before the first cycle rather than after it. Triple-negative breast cancer is diagnosed in younger women more often than the other subtypes, and treatment given before surgery starts months of drug therapy at exactly the point where fertility decisions have to be made. Raise it at the planning appointment, not once treatment is under way — our page on fertility and pregnancy on immunotherapy sets out what is known, what is genuinely uncertain, and what can be arranged in the gap before cycle one.

Related reading

• Immunotherapy for Triple-Negative Breast Cancer — the wider picture: who qualifies in early disease, what a PD-L1 score changes in advanced disease, and why the two sets of rules are different.
• Fertility and Pregnancy on Immunotherapy — the conversation to have before the first cycle, and why long-term fertility data after immunotherapy is still genuinely immature.
• Immunotherapy for Cervical Cancer — how eligibility is decided in a gynaecological cancer where checkpoint inhibitors also have a defined, and similarly narrow, place.
• Immunotherapy for Endometrial and Uterine Cancer — where a biomarker rather than the subtype opens the option, which is a useful contrast with the breast pathway on this page.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, how response scans are coordinated with our partner imaging centres, and how costs are set out in writing.

CION is a woman-headed organisation and breast cancer is the disease our teams see most. Every consultation is 45 minutes, every plan goes to a tumour board, and no test is ordered that will not change a decision. If surgery has been offered to you and nobody has explained why it is first or second in the plan, that is exactly the question a second opinion is for.

This page is general information and does not replace a consultation. It describes treatment classes only, not specific medicines or brands, and it recommends no treatment. Eligibility criteria, subtype proportions and treatment schedules are drawn from NCCN, ASCO and ESMO patient-education guidance current in August 2026 and can change; no outcome or survival figure of any kind is stated or implied. Every decision about your treatment belongs with your own treating team.

Get a second opinion before the surgery date is fixed

Free, written, and reviewed by our tumour board — so you know why each treatment is in your plan, and why it is in that order.